CoChat

Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy

Open access
Uribesalgo, Iris, Hoffmann, David, Zhang, Yin, Kavirayani, Anoop, Lazovic, Jelena, Berta, Judit, Novatchkova, Maria, Pai, Tsung‐Pin, Wimmer, Reiner A, László, Viktória, Schramek, Daniel, Karim, Rezaul, Tortola, Luigi, Deswal, Sumit, Haas, Lisa, Zuber, Johannes, Szűcs, Miklós, Kuba, Keiji, Dome, Balazs, Cao, Yihai, Haubner, Bernhard J, Penninger, Josef M · 2019 · EMBO Molecular Medicine
Cited by 114

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Angiogenesis is a hallmark of cancer, promoting growth and metastasis. Anti‐angiogenic treatment has limited efficacy due to therapy‐induced blood vessel alterations, often followed by local hypoxia, tumor adaptation, progression, and metastasis. It is therefore paramount to overcome therapy‐induced resistance. We show that Apelin inhibition potently remodels the tumor microenvironment, reducing angiogenesis, and effectively blunting tumor growth. Functionally, targeting Apelin improves vessel function and reduces polymorphonuclear myeloid‐derived suppressor cell infiltration. Importantly, in mammary and lung cancer, Apelin prevents resistance to anti‐angiogenic receptor tyrosine kinase (RTK) inhibitor therapy, reducing growth and angiogenesis in lung and breast cancer models without increased hypoxia in the tumor microenvironment. Apelin blockage also prevents RTK inhibitor‐induced metastases, and high Apelin levels correlate with poor prognosis of anti‐angiogenic therapy patients. These data identify a druggable anti‐angiogenic drug target that reduces tumor blood vessel densities and normalizes the tumor vasculature to decrease metastases. Apelin is an angiogenic peptide implicated in embryonic and tumor angiogenesis. This study highlights Apelin targeting as a cancer therapy alone or in combination with current anti‐angiogenic therapies to reduce tumour growth and improve vessel structure and functionality, and thus survival. Apelin is an angiogenic peptide implicated in embryonic and tumor angiogenesis. This study highlights Apelin targeting as a cancer therapy alone or in combination with current anti‐angiogenic therapies to reduce tumour growth and improve vessel structure and functionality, and thus survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201809266

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 114

Metadata

Authors
Uribesalgo, I., Hoffmann, D., Zhang, Y., Kavirayani, A., Lazovic, J., Berta, J., Novatchkova, M., Pai, T., Wimmer, R. A., László, V., Schramek, D., Karim, R., Tortola, L., Deswal, S., Haas, L., Zuber, J., Szűcs, M., Kuba, K., Dome, B., Cao, Y., Haubner, B. J., & Penninger, J. M.
Venue
EMBO Molecular Medicine
Published
2019-06-24
Volume
11
Issue
8
Pages
e9266-e9266
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2952975115
Cited by
114
References
16
FWCI
8.62
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy. https://app.cochat.ai/papers/10.15252/emmm.201809266
The paper
Uribesalgo, I., Hoffmann, D., Zhang, Y., Kavirayani, A., Lazovic, J., Berta, J., Novatchkova, M., Pai, T., Wimmer, R. A., László, V., Schramek, D., Karim, R., Tortola, L., Deswal, S., Haas, L., Zuber, J., Szűcs, M., Kuba, K., Dome, B., . . . Penninger, J. M. (2019). Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201809266

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.